Skip to main content
. 2023 Aug 2;8(6):e10579. doi: 10.1002/btm2.10579

FIGURE 4.

FIGURE 4

Strategies for anti‐hepatic fibrogenesis. (a) Human high mobility group box‐1‐siRNA@SNALP‐pPB effectively alleviate liver fibrosis. (b) The modification of pPB increases the accumulation of SNALP in the liver. Reproduced with permission from Reference 73, copyright 2020, American Chemical Society. (c) Schematic illustration of the miRNA loaded vitamin A‐modification of superparamagnetic iron oxide alleviating liver fibrosis. Reproduced with permission from Reference 74, copyright 2019, Wiley. (d) The Vismodegib loaded RGDLip/VIS reduced hepatic fibrosis by inhibiting hedgehog signaling in bile duct ligation and thioacetamide mice models. Reproduced with permission from Reference 87, copyright 2019, Elsevier. (e) Nanoparticles designed to deliver mRNA for recovery of hepatocytes. Reproduced with permission from Reference 94, copyright 2021, Elsevier. (f) The assembly of doxorubicin‐retinoic acid‐chondroitin sulfate micelles targeting the Golgi apparatus by N‐acetylgalactosaminyltransferase decoration. Reproduced with permission from Reference 100, copyright 2019, American Chemical Society. (g) The schematic illustration of gold nanorods‐PDGFRβ‐mediated photothermal therapy decreases carbon tetrachloride induced hepatic fibrosis in a mice model. Reproduced with permission from Reference 102, copyright 2021, American Chemical Society.